The United Kingdom is taking another significant step towards reshaping how medicines and medical devices are regulated.
On 1 September 2026, the Government announced that it had tabled three amendments to the Health Bill designed to modernise the legislative framework supporting the Medicines and Healthcare products Regulatory Agency (MHRA). The proposals cover three connected areas: information sharing, a more adaptable regulatory system, and enabling powers for a possible future medical device licensing regime.
At first glance, these amendments may appear highly technical. In practice, they could influence how quickly regulators respond to scientific developments, how information moves between trusted regulators, how manufacturers prepare for regulatory change, and eventually how certain medical devices reach the Great Britain market.
But there is an important point to understand at the outset.
These amendments do not immediately create a new medical device licensing system or change the current regulatory requirements for medicines and medical devices. They are intended to create the legislative foundations for future reforms. The proposals still have to go through Parliament, and any future regulatory model would require further policy development, consultation, impact assessment and scrutiny.
That makes this announcement less about an immediate rule change and more about the direction in which UK regulation is heading.
For manufacturers, healthcare organisations, technology developers, investors, clinicians and patients, that direction matters.
What Has the Government Proposed?
The Government has tabled three amendments to the Health Bill.
They focus on:
- Information-sharing powers for medicines and medical devices
- Making medicines and medical device legislation easier and faster to update
- Creating enabling powers for a potential future medical device licensing regime
Together, the proposals are intended to make the UK’s regulatory system more flexible while maintaining safeguards around patient safety, commercially sensitive information and parliamentary oversight.
The changes form part of a wider programme of MHRA and UK medical-device regulatory reform.
The wider programme is already moving in several directions. The Government has been working on future medical-device regulations, international reliance, CE recognition, UKCA arrangements, post-market surveillance and requirements intended to make the system more proportionate and responsive to innovation.
The September 2026 amendments therefore need to be viewed as one part of a much larger regulatory transition.
Why Is the UK Reforming the MHRA Regulatory Framework?
Medical technology is changing faster than traditional legislation can sometimes accommodate.
A medical device is no longer necessarily a physical piece of equipment sitting in a hospital.
Modern healthcare products can include:
- AI-enabled diagnostic systems
- Clinical software
- Remote monitoring technologies
- Connected medical devices
- Digital therapeutics
- Advanced implants
- Wearable technologies
- Software that continuously analyses patient information
- Artificial intelligence used to support clinical decisions
This creates a regulatory challenge.
A regulatory framework designed around relatively stable physical products can struggle when technologies are updated through software, connected to cloud platforms or improved through rapidly evolving algorithms.
The Government’s wider future-regulatory programme recognises this challenge. The stated aim is to create a framework that prioritises patient safety while also enabling access to innovative medical technologies and supporting the UK’s MedTech sector.
The latest amendments continue that direction.
The basic question is no longer simply:
“Does this device meet today’s regulatory requirements?”
It increasingly becomes:
“Can the regulatory system itself keep pace with tomorrow’s technology?”
That is one of the central reasons these reforms matter.
1. New Information-Sharing Powers: Why They Matter
The first amendment concerns information sharing.
The proposal would give the MHRA clearer legal powers to share specific information relating to medicines and medical devices with trusted UK Government organisations and international regulatory partners.
The purpose is not simply to exchange information for administrative convenience.
The Government says information sharing could support:
- Public health
- Patient safety
- Access to innovation
- Effective regulation
- Cooperation with trusted international regulators
Why does information sharing matter?
Regulatory authorities increasingly deal with products that are sold across multiple countries.
A medical device may be developed in one country, assessed in another, manufactured somewhere else and used by patients across several healthcare systems.
A safety signal detected in one market can therefore become important to regulators elsewhere.
Imagine that a regulator identifies an unexpected safety issue with a connected medical device.
If regulators can lawfully and appropriately share relevant information, another authority may be able to assess the same product sooner rather than waiting for the issue to emerge independently.
That can potentially shorten the distance between:
safety signal → regulatory assessment → action → patient protection.
The same principle can apply to medicines.
International regulatory cooperation can help authorities make better use of existing regulatory evidence rather than duplicating every activity from the beginning.
The MHRA already uses international approaches in some areas. For example, its International Recognition Procedure for medicines allows the agency to use approvals from trusted regulatory partners as part of a route intended to support expedited access to medicines.
The proposed legislative changes could provide a clearer statutory foundation for information sharing across a wider regulatory context.
Patient Privacy and Commercially Sensitive Information
Information sharing naturally raises another question:
What information will actually be shared, and how will sensitive information be protected?
The Government has stressed that existing safeguards will remain.
Information sharing would be subject to statutory criteria and proportionality requirements. Patient information and commercially sensitive information would continue to receive protection through applicable safeguards, including data protection requirements and patient consent where relevant.
This is important because regulatory information can be commercially significant.
Manufacturers may provide regulators with:
- Technical information
- Mmanufacturing information
- Clinical evidence
- Safety data
- Product-development information
- Proprietary processes
- Information relating to ongoing investigations
A modern regulatory system needs to balance two competing requirements.
On one side is greater regulatory cooperation.
On the other is protection of confidential and personal information.
The proposed amendment is intended to give the MHRA clearer powers to operate within that balance.
2. Making UK Regulation Easier to Update
The second amendment addresses one of the biggest structural challenges in regulation: keeping legislation current.
Science does not wait for Parliament.
Technology does not wait for a five-year legislative cycle.
International standards can change.
Technical guidance can evolve.
New scientific knowledge can emerge.
Medical-device standards may need to respond to new risks and new technologies.
The proposed reforms would make it easier for UK legislation to reflect future updates to certain documents, including technical standards and international guidelines.
This could create a more dynamic regulatory environment.
From Static Rules to a More Responsive Framework
Traditional legislation tends to be relatively fixed.
Once Parliament passes a law, changing it can require another legislative process.
That is appropriate for major policy decisions, but it can become cumbersome when the change is technical.
For example, suppose an internationally recognised technical standard changes because scientific understanding has improved.
A regulatory system may need to reflect that development.
The proposed approach could allow certain future updates to be incorporated more efficiently.
The objective is not to remove parliamentary oversight.
Instead, the Government proposes a framework under which certain technical, administrative or minor regulatory changes could become part of legislation unless Parliament objects, while significant policy changes would continue to receive fuller scrutiny.
This distinction is important.
The proposal is effectively trying to separate:
technical evolution
from
major policy decisions.
That could make the regulatory system faster without treating major changes as purely administrative matters.
What Could Faster Regulatory Updates Mean for Manufacturers?
For manufacturers, regulatory uncertainty can be expensive.
Companies need to make decisions years in advance about:
- Product development
- Clinical evidence
- Technical documentation
- Manufacturing
- Quality management
- Regulatory submissions
- Market entry
- Post-market monitoring
- Investment
A regulatory framework that can respond more efficiently to scientific and technical developments could eventually reduce some forms of regulatory friction.
However, faster regulation does not automatically mean easier regulation.
In some circumstances, faster updates could also require manufacturers to monitor regulatory developments more closely.
Companies may need stronger regulatory intelligence functions.
They may need to track:
- changes to technical standards
- international guidance
- MHRA consultations
- new statutory instruments
- updated conformity requirements
- post-market surveillance expectations
The future regulatory environment may therefore become more responsive but also more dynamic.
Manufacturers that treat compliance as a one-time activity may find that approach increasingly difficult to sustain.
Proportionate Consultation: What Could Change?
The Government is also proposing a more proportionate approach to consultation.
Under the proposal, minor changes could involve targeted engagement rather than the same level of consultation required for major reforms.
At the same time, significant policy reforms would continue to require full public consultation.
This is a practical distinction.
Not every regulatory amendment has the same impact.
Changing a technical reference may not require the same consultation process as introducing a completely new safety obligation.
A proportionate approach could therefore help the regulatory system move more quickly where the change is limited.
For industry, however, this makes stakeholder engagement even more important.
Manufacturers, professional organisations, clinicians and other affected groups may need to respond quickly when targeted consultations are launched.
3. The Most Significant Proposal: Future Medical Device Licensing
The third amendment could have the biggest long-term impact on the medical-device sector.
The Government is proposing enabling powers that could support the future development of a medical device licensing regime.
The amendment would modify the Medicines and Medical Devices Act 2021 to create a legal foundation for developing such a framework.
But this needs to be understood carefully.
A licensing system is not being introduced immediately.
The amendment would create enabling powers.
The detailed model would still need to be developed through:
- policy work
- stakeholder engagement
- public consultation
- impact assessment
- parliamentary scrutiny
That means manufacturers should not interpret the announcement as an instruction to immediately obtain a new MHRA device licence.
There is no such immediate requirement under this announcement.
What Could a Future Medical Device Licence Look Like?
The Government is exploring an approach under which medical devices entering the Great Britain market through a domestic route could eventually require an MHRA-issued licence.
This could represent a significant change from the traditional reliance on third-party conformity assessment for certain products.
The important phrase is:
“under the approach being explored.”
The final model has not yet been established.
The future system would need to determine questions such as:
- Which devices would require a licence?
- Would every device be licensed?
- How would risk classification affect licensing?
- What evidence would manufacturers need?
- How would existing UKCA routes interact with licensing?
- What would happen to internationally recognised devices?
- How would software and AI devices be assessed?
- What would licence renewal look like?
- How would post-market surveillance connect with licensing?
- What transitional arrangements would apply?
These are precisely the issues that future policy development and consultation would need to address.
A Risk-Based Licensing System
One of the most important principles mentioned by the Government is proportionality.
The future licensing framework is expected to be designed around risk, with different levels of scrutiny depending on the nature of the product.
That is significant.
A low-risk device should not necessarily face the same regulatory burden as a high-risk implant or a device involved in critical clinical decisions.
A risk-based system could potentially divide regulatory scrutiny according to factors such as:
- intended purpose
- patient risk
- invasiveness
- duration of use
- clinical significance
- software functionality
- degree of autonomy
- potential consequences of failure
This approach becomes particularly relevant as artificial intelligence enters medical technology.
Why AI Medical Devices Are Part of the Conversation
Artificial intelligence creates regulatory problems that conventional devices do not always present.
A physical device may remain substantially unchanged after approval.
AI-enabled software can be different.
Algorithms may be updated.
Models may be retrained.
Performance can vary across populations.
Data quality can influence outcomes.
A system may interact with other software or healthcare infrastructure.
This creates questions about the entire lifecycle of a medical device.
Regulators increasingly need to consider not only:
“Was this device safe when it was assessed?”
but also:
“How will we know whether it remains safe and effective as it is used, updated and deployed in the real world?”
The MHRA has specifically identified advancing medical technologies, including software and AI medical devices, as part of the reason for developing a more modern and adaptable framework.
This is likely to become one of the defining regulatory issues of the next decade.
The Future System Will Not Start From Zero
Although the proposed licensing powers are new, the UK has already been developing a broader future medical-device framework.
The Government’s wider programme has included reforms covering market access, international reliance, UKCA, in vitro diagnostic devices and post-market surveillance.
The objective is a more proportionate and phased implementation that supports system readiness and reduces the risk of disruption to patient supply.
This is important for manufacturers.
The regulatory landscape should not be viewed as one single reform arriving on one date.
It is better understood as a sequence of connected changes.
UKCA Is Not Being Replaced Immediately
Another point that manufacturers need to understand is the status of UKCA.
The September 2026 announcement confirms that the UKCA regime will remain in place in Great Britain while any future licensing model is developed. The Government also says that its policy intentions around international reliance and recognition remain unchanged.
Therefore, businesses should not assume that the announcement means UKCA has suddenly disappeared.
The current system continues to operate while the future framework is developed.
This creates an important planning principle:
Comply with the rules that apply today while preparing for the direction of travel tomorrow.
CE Marked Devices and the UK Market
The situation is also more complicated because Great Britain currently permits certain CE-marked medical devices to access its market under transitional arrangements.
Government guidance states that manufacturers can access the Great Britain market through UKCA certification or recognised CE certification, with CE recognition currently subject to different timelines depending on the relevant EU legislation.
In February 2026, the MHRA also launched a consultation on proposals concerning indefinite recognition of CE-marked medical devices in Great Britain. The consultation highlighted the importance of maintaining patient access and supply, noting that around 90% of medical devices currently used in Great Britain are CE marked.
That figure explains why market-access policy cannot be changed overnight.
A sudden regulatory switch could create supply problems.
Hospitals depend on medical devices already available through international supply chains.
Manufacturers need time to understand new requirements.
Regulators need capacity.
Approved bodies need capacity.
Healthcare providers need continuity.
Patients ultimately need uninterrupted access to safe products.
The Government’s broader implementation approach therefore emphasises a phased transition.
International Reliance: Another Major Part of the Future
The proposed licensing powers should also be viewed alongside the UK’s work on international reliance.
The MHRA has been developing approaches that could allow regulatory decisions and assessments made by trusted international regulators to support access to the Great Britain market.
The policy work has considered regulators in jurisdictions including:
- Australia
- Canada
- the European Union
- the United States
The Government has also been considering wider international regulatory cooperation.
International reliance is important because regulators do not necessarily need to repeat every assessment independently.
Instead, a regulator can make significant use of trusted work already performed elsewhere while retaining responsibility for its own regulatory decisions.
That can potentially reduce duplication.
It can also help manufacturers avoid repeatedly submitting essentially the same evidence to multiple regulators.
Why International Reliance Could Benefit Patients
The benefit is not limited to industry.
It could affect patients directly.
Suppose an innovative medical technology has already been assessed by a trusted regulator and has substantial evidence supporting its safety and performance.
A reliance-based pathway could potentially allow the UK regulator to use that information rather than starting from the same point.
The result could be:
less duplication → faster regulatory decision-making → earlier access to suitable technology.
The MHRA has previously described reliance on other regulators as a way to make regulatory oversight more efficient while retaining regulatory responsibility.
But reliance is not the same as automatic acceptance.
The MHRA would retain regulatory authority.
That distinction matters.
Post-Market Surveillance Will Become Increasingly Important
Regulation does not end when a product reaches the market.
In fact, for many medical devices, that is when the real-world evidence begins to accumulate.
A device may behave differently in widespread clinical use than it did during controlled testing.
New risks can emerge.
Rare adverse events can become visible.
Software can introduce new functionality.
Manufacturing changes can affect performance.
Users may discover problems that were not obvious during development.
This is why post-market surveillance is becoming a central component of the UK’s future framework.
The Government’s future medical-device programme includes stronger post-market requirements and measures designed to improve traceability and patient safety.
Recent proposals have included requirements involving unique device identifiers, implant cards, technical-document retention and other measures designed to strengthen oversight across the device lifecycle.
A future licensing system could therefore become part of a broader lifecycle model rather than simply another approval certificate.
What Does This Mean for Medical Device Manufacturers?
For manufacturers, the message is not “change everything immediately.”
The better message is:
start preparing strategically.
Companies operating in Great Britain should keep a close watch on regulatory developments and understand how their products fit into the evolving framework.
Areas worth reviewing include:
1. Product classification
Manufacturers should understand how their products are classified under current and proposed UK rules.
Classification can influence regulatory scrutiny, evidence requirements and market access.
2. Technical documentation
Companies should maintain clear, current technical files.
As regulation becomes more dynamic, outdated documentation could become a significant weakness.
3. Clinical evidence
Manufacturers should ensure that evidence supporting safety and performance remains robust and relevant.
4. Post-market surveillance
Companies should strengthen systems for identifying, analysing and responding to safety signals.
5. Software and AI governance
Developers of software and AI medical devices should consider how product changes, updates, data and algorithm performance will be managed throughout the lifecycle.
6. International approvals
Manufacturers with approvals in trusted international jurisdictions should monitor developments around UK reliance pathways.
7. Regulatory intelligence
Regulatory monitoring should become a continuous function rather than something undertaken only when a product is approaching launch.
What Does This Mean for Healthcare Providers?
Hospitals, clinics and healthcare organisations are also stakeholders in the regulatory transition.
They may eventually benefit from:
- improved device traceability
- clearer safety information
- stronger post-market monitoring
- potentially faster access to innovative devices
- improved information sharing between regulators
The future framework could also provide better mechanisms for responding to emerging safety concerns.
For healthcare providers, procurement teams will need to remain aware of changing market-access requirements.
A device that is available under today’s framework may face different requirements under a future system.
That makes regulatory awareness increasingly important for procurement and supply-chain planning.
What Does This Mean for Patients?
Patients are ultimately at the centre of the regulatory system.
The success of reform should not be measured simply by how quickly a product receives approval.
It should be measured by whether patients can access safe, effective and appropriate technologies without unnecessary delays.
The Government’s stated objectives include patient safety, access to innovation and maintaining supply.
A successful future system should therefore achieve several things at once:
Safety
Patients need confidence that medical devices are properly assessed and monitored.
Access
Innovative technologies should not face unnecessary regulatory delays.
Transparency
Patients and healthcare professionals should receive meaningful information about devices.
Traceability
Regulators should be able to identify products and respond quickly when problems occur.
Continuity
Regulatory reform should not unintentionally disrupt supplies.
That balance will be one of the biggest tests of the future framework.
Great Britain and Northern Ireland: An Important Difference
The regulatory picture is not identical across the whole UK.
The September 2026 MHRA announcement specifically states that Northern Ireland continues to apply the EU Medical Device and In Vitro Diagnostic Regulations under the Windsor Framework. This supports Northern Ireland’s dual market access to the EU Single Market and the UK internal market.
This means businesses operating across the UK cannot assume that one set of medical-device requirements will automatically apply everywhere.
For manufacturers and distributors, geographic scope remains an important part of regulatory planning.
The distinction between:
Great Britain — England, Scotland and Wales
and
Northern Ireland
must continue to be considered when planning market access.
The Likely Road Ahead
The September 2026 amendments are enabling measures.
The next stages will involve parliamentary consideration and, if the amendments progress, further policy development.
The Government has indicated that the future licensing framework would require further consultation, impact assessment and parliamentary scrutiny before implementation.
A sensible way to understand the likely process is:
Stage 1: Parliamentary consideration
The amendments will be examined as part of the Health Bill’s remaining stages.
Stage 2: Policy development
The Government and MHRA would develop the detailed architecture of any future licensing regime.
Stage 3: Stakeholder consultation
Manufacturers, healthcare professionals, patients, industry groups and other stakeholders would have opportunities to provide views.
Stage 4: Impact assessment
The Government would assess the potential economic, regulatory and operational consequences.
Stage 5: Detailed legislation and rules
The framework would need detailed legal and regulatory provisions.
Stage 6: Implementation planning
Businesses and regulators would need time to prepare systems, guidance and processes.
Stage 7: Transition
Any future system would need appropriate transitional arrangements to reduce disruption.
This is why businesses should not treat 1 September 2026 as a sudden compliance deadline.
It is a strategic warning and planning signal.
What Businesses Should Do Now
There are several practical steps manufacturers can take without waiting for the final licensing regime.
Audit the current regulatory position
Identify exactly how each product currently enters the Great Britain market.
Is it:
- UKCA?
- CE recognition?
- Another permitted route?
- A product relying on transitional arrangements?
Understanding the current position is the foundation for future planning.
Map regulatory dependencies
Identify which standards, certificates, assessments and external organisations your products depend upon.
This becomes especially important if the legislative framework becomes more responsive to changes in international standards.
Review international approvals
If your device is already approved in Australia, Canada, the EU or the US, assess how future UK reliance arrangements could affect your strategy.
Do not assume international approval automatically guarantees UK market access.
Strengthen surveillance
Post-market surveillance should be treated as a strategic capability, not simply a compliance exercise.
Prepare for more regulatory change
Companies should build regulatory change management into product planning.
A product lifecycle should account for potential changes in:
- classification
- evidence
- standards
- labelling
- traceability
- surveillance
- software updates
- regulatory submissions
Watch MHRA consultations
Consultations can provide an early view of where the framework is heading.
For larger manufacturers, this may also be the stage at which industry feedback can influence the final design.
The Bigger Picture: A Shift Towards a More Adaptive Regulator
The most interesting aspect of the September 2026 announcement may not be the proposed licensing regime alone.
It is the broader philosophy behind the reforms.
The Government is attempting to build a regulatory system that can respond more effectively to:
- scientific advances
- digital healthcare
- artificial intelligence
- international regulatory developments
- emerging safety information
- new medical technologies
That requires more than changing one regulation.
It requires a system capable of learning.
A medical device framework designed for the technologies of yesterday may become increasingly unsuitable for the technologies of tomorrow.
AI is one example.
Connected healthcare is another.
Software-based medical devices are another.
The regulatory framework needs to evolve alongside them.
The Potential Benefits of the Reform
If implemented carefully, the reforms could offer several long-term benefits.
Better patient protection
Improved information sharing and post-market oversight could help regulators identify risks more effectively.
Faster access to innovation
International reliance and more responsive regulatory processes could potentially reduce unnecessary duplication and delays.
More resilient regulation
A licensing framework could give the MHRA greater direct regulatory capability and support regulatory resilience.
Better response to AI and software
A modern framework could be better suited to technologies that evolve after initial market entry.
More proportionate regulation
Different products could receive different levels of scrutiny according to their risk.
Greater international cooperation
Closer cooperation with trusted regulators could improve regulatory efficiency.
More adaptable legislation
The ability to reflect appropriate technical and international updates more efficiently could reduce regulatory lag.
These benefits, however, will depend heavily on implementation.
The Risks and Challenges
Regulatory reform also brings challenges.
A more flexible framework could create uncertainty if businesses do not have enough advance notice of changes.
New licensing requirements could increase compliance costs.
Smaller medical-device companies may find it harder to absorb additional regulatory work.
Manufacturers may need to maintain multiple regulatory strategies for Great Britain, Northern Ireland and other international markets.
There is also a delicate balance between faster decision-making and thorough scrutiny.
Faster does not necessarily mean better.
The objective should be smarter regulation—not simply quicker regulation.
That is why consultation, impact assessment and parliamentary scrutiny remain important parts of the proposed process.
What the Reform Could Mean for the UK’s MedTech Ambitions
The UK wants to remain an attractive location for medical innovation.
The Government’s wider medical-device programme is designed around a combination of patient safety, innovation and market access. In May 2026, the MHRA said proposed changes were intended to support faster access to safe and innovative devices and economic growth in the UK MedTech sector.
This creates an important policy challenge.
If regulation is too weak, patient safety can suffer.
If regulation is unnecessarily slow or fragmented, innovation can suffer.
If regulation is unpredictable, investment can suffer.
The future system therefore needs to find a middle ground:
strong enough to protect patients, flexible enough to support innovation, and predictable enough for businesses to invest.
That is arguably the central test for the MHRA reforms.
Final Thoughts: What Happens Next?
The MHRA’s 1 September 2026 announcement should not be interpreted as the immediate introduction of a new medical device licensing requirement.
Instead, it signals the next stage of a much broader transformation of the UK’s medical-device regulatory system.
The three amendments have a clear common theme:
make the regulatory framework more capable of responding to change.
The information-sharing proposal aims to strengthen cooperation.
The regulatory reform proposal aims to make the legislative framework more adaptable.
The medical-device licensing proposal aims to create the legal foundation for a potential future domestic licensing system.
At the same time, the UK is continuing work on international reliance, CE recognition, UKCA, post-market surveillance and future medical-device regulations.
For manufacturers, the immediate priority is not to react to a licence that does not yet exist.
It is to understand the direction of travel.
Businesses should continue complying with the current rules while strengthening regulatory intelligence, technical documentation, post-market surveillance and long-term market-access planning.
For healthcare providers, the focus should be on supply continuity, procurement awareness and patient safety.
For patients, the ultimate objective is straightforward: a regulatory system capable of providing access to safe and effective medical technologies while responding quickly when something goes wrong.
The UK is now trying to build that system.
The legislation announced in September 2026 is one more step towards it.
Key Takeaways
- The Government has tabled three MHRA-related amendments to the Health Bill.
- The proposals cover information sharing, regulatory flexibility and future medical device licensing powers.
- No new medical device licence is being introduced immediately.
- Any future licensing regime would require further policy development, consultation, impact assessment and parliamentary scrutiny.
- The proposed framework could allow the MHRA to use clearer powers to share relevant information with trusted UK and international partners.
- The reforms could make it easier for UK legislation to respond to technical standards and international guidance.
- UKCA remains in place in Great Britain while a future licensing model is developed.
- Northern Ireland continues to operate under the EU medical-device framework through the Windsor Framework.
- International reliance remains an important part of the UK’s wider medical-device regulatory strategy.
- AI and software-based medical devices are likely to be increasingly important to future regulation.
- Manufacturers should monitor MHRA consultations and begin long-term regulatory planning now.
- The ultimate objective is a system that combines patient safety, innovation, regulatory resilience and reliable access to medical technology.
Frequently Asked Questions
What are the new MHRA amendments to the Health Bill?
The Government has tabled three amendments covering information-sharing powers, regulatory reform measures and enabling powers for the possible future development of a medical device licensing regime.
Will medical device manufacturers need an MHRA licence immediately?
No. The proposals do not introduce an immediate medical device licensing requirement. The proposed licensing powers would provide a legal foundation for developing a future regime, which would require further policy development, consultation, impact assessment and parliamentary scrutiny.
Is UKCA being abolished?
The September 2026 announcement does not abolish UKCA. The Government states that the UKCA regime will remain in place in Great Britain while a potential future licensing model is developed.
What is the purpose of the proposed information-sharing powers?
The proposal is intended to give the MHRA clearer legal powers to share relevant medicines and medical-device information with trusted UK Government organisations and international regulatory partners where this supports public health, patient safety, innovation and effective regulation.
Will patient information be shared freely?
No. The Government says information sharing would remain subject to statutory criteria, proportionality requirements and safeguards, including data protection legislation and patient-consent requirements where applicable.
How could the reforms affect AI medical devices?
The future framework is intended to be more adaptable to emerging technologies, including software and AI medical devices. This could become increasingly important as medical technologies evolve through software updates, algorithms and connected systems.
What is international reliance for medical devices?
International reliance involves a regulator taking into account and giving significant weight to assessments or regulatory decisions made by another trusted regulator while retaining responsibility for its own decision. The UK has been developing this approach as part of its future medical-device framework.
Does Northern Ireland follow the same medical device rules as Great Britain?
No. Northern Ireland continues to apply the EU Medical Device and In Vitro Diagnostic Regulations under the Windsor Framework, supporting its access to both the EU Single Market and the UK internal market.
What should medical device companies do now?
Companies should continue meeting current regulatory requirements while monitoring MHRA developments, reviewing their market-access routes, maintaining technical documentation, strengthening post-market surveillance and assessing how future UK reforms could affect their products.
When will the new medical device licensing system begin?
There is currently no confirmed implementation date for a future licensing regime because the proposed amendment is intended to provide enabling powers for further development. The detailed framework would need to be developed and subjected to consultation, impact assessment and parliamentary scrutiny.
Conclusion
The UK’s medical-device regulatory system is entering another important phase.
The latest MHRA amendments do not represent an overnight regulatory overhaul. They represent something more structural: an attempt to give the UK’s regulatory system the flexibility and legal foundations it may need to keep pace with modern healthcare.
For manufacturers, this means planning ahead.
For regulators, it means balancing speed with safety.
For healthcare providers, it means preparing for a more dynamic market-access environment.
And for patients, the promise is ultimately about something much simpler: safe medical technology reaching people when they need it, backed by a regulatory system capable of keeping up with change.
The real impact of the September 2026 proposals will become clearer as Parliament considers the amendments and the Government develops the detailed policy behind them.
For now, the message from the MHRA is clear: the UK’s medical-device regulatory framework is being designed for a future in which technology, international cooperation and patient expectations are changing faster than ever.